<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199026</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0171</org_study_id>
    <secondary_id>NCI-2019-05820</secondary_id>
    <secondary_id>2019-0171</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>R01CA180279</secondary_id>
    <nct_id>NCT04199026</nct_id>
  </id_info>
  <brief_title>Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma</brief_title>
  <official_title>Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies the side effects of implanting and removing a microdevice in
      patients with sarcomas that have spread to other places in the body (metastatic) or have come
      back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue
      and are loaded with 10 different drugs that are delivered at very small doses, or
      &quot;microdoses,&quot; which may only affect a very small, local area inside the tumor. The purpose of
      this study is to determine which drugs delivered in the microdevice affect tumor tissue in
      patients with sarcomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the safety of drug delivery microdevice (microdevice) placement and removal in
      subjects undergoing resection of sarcoma.

      II. Determine the technical feasibility of microdevice placement and removal with intact
      surrounding tissue in subjects undergoing resection of a sarcoma.

      SECONDARY OBJECTIVE:

      I. Use the intratumoral cellular response to evaluate individual agents and/or drug
      combinations released from the microdevice reservoirs to assess the relative drug efficacy
      across all individual agents or drug combinations tested using the microdevice technology.

      EXPLORATORY OBJECTIVES:

      I. Evaluate the microdevice performance for its capacity to predict Response Evaluation
      Criteria in Solid Tumors (RECIST) response in the subset of patients that receive systemic
      chemotherapies as part of their standard-of-care or clinical trial treatments. II. Determine
      genomic, transcriptomic, and proteomic predictive biomarkers from resected specimens that
      correlate with local (i.e. microdevice-based) and systemic drug response. III. Determine, at
      a single-cell level, proteomic traits associated with chemosensitivity versus (vs.)
      resistance using mathematical notions of network robustness and fragility.

      OUTLINE:

      Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days
      before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide,
      vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab,
      and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of
      surgery 2 days later, patients have the drug delivery microdevice(s) removed. Conditions
      Conditions: Metastatic Sarcoma Recurrent Sarcoma
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 4, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the safety and technical feasibility of microdevice insertion/removal, as assessed by adverse events by CTCAE 5.0.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Assess the safety of microdevice placement and removal in subjects undergoing resection of sarcoma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess efficacy across all individual agents or drug combinations tested using the microdevice technology.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The primary outcome measure is the number of participants that experience a grade 3 or 4 adverse event, as defined by CTCAE 5.0. A second primary outcome measure of device technical feasibility measures the number of devices that successfully generate high-quality data from each of at least 50% of the patients enrolled. A successful device is one that generated high-quality data from at least 40% of the drugs in the device by IHC and/or other methodologies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the drug antineoplastic drug effects observed in the adjacent tumor tissues following exposure to drug micro-doses released by each microdevice reservoir.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The degree of cell apoptosis and cell proliferation observed in the adjacent tumor tissues will be compared for the placebo control (i.e. PEG) to gauge the antineoplastic effect elicited by each of the drug micro-doses released by the respective microdevice reservoirs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Sarcoma</condition>
  <condition>Recurrent Sarcoma</condition>
  <condition>Resectable Sarcoma</condition>
  <arm_group>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin HCl</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Delivery Microdevice</intervention_name>
    <description>Undergo percutaneous implantation of drug delivery microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>Microdevice</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>42-O-(2-Hydroxy)ethyl Rapamycin</other_name>
    <other_name>Afinitor</other_name>
    <other_name>Certican</other_name>
    <other_name>RAD 001</other_name>
    <other_name>RAD001</other_name>
    <other_name>Votubia</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ganitumab</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>AMG 479</other_name>
    <other_name>Anti-IGF-1R Human Monoclonal Antibody AMG-479</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>GW786034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>Glycol, polyethylene</other_name>
    <other_name>PEG</other_name>
    <other_name>Poly(oxyethylene)</other_name>
    <other_name>Polyethylene Glycol 400</other_name>
    <other_name>Polyethylene Glycol 8000</other_name>
    <other_name>POLYETHYLENE GLYCOL, UNSPECIFIED</other_name>
    <other_name>Polyethylene Oxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>CCRG-81045</other_name>
    <other_name>Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-</other_name>
    <other_name>M &amp; B 39831</other_name>
    <other_name>M and B 39831</other_name>
    <other_name>Methazolastone</other_name>
    <other_name>RP-46161</other_name>
    <other_name>SCH 52365</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>Temomedac</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>CCI-779 Rapamycin Analog</other_name>
    <other_name>Cell Cycle Inhibitor 779</other_name>
    <other_name>Rapamycin Analog</other_name>
    <other_name>Rapamycin Analog CCI-779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo standard of care surgery</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given via microdevice</description>
    <arm_group_label>Device Feasibility (microdevice, surgery)</arm_group_label>
    <other_name>LEUROCRISTINE</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is
             indicated as a standard of care.

          -  10 years of age or older

          -  Documented, signed, dated informed consent to participate in the microdevice study

          -  ECOG performance status of &lt;/= 2

        Exclusion:

          -  Subjects who do not wish to undergo surgical resection, or those who are high-risk or
             not candidates for surgical resection

          -  Age &lt; 10 years old

          -  Women of childbearing potential without a negative pregnancy test; or women who are
             lactating

          -  Allergies or prior adverse drug reactions to any of the drugs loaded within the
             microdevice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Ludwig</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph A Ludwig</last_name>
    <phone>713-792-3626</phone>
    <email>jaludwig@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph A. Ludwig</last_name>
      <phone>713-792-3626</phone>
    </contact>
    <investigator>
      <last_name>Joseph A. Ludwig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

